World Health Organization. Global tuberculosis report, 2013.
King, L, Munsiff, S, Ahuja, S.
Achieving international targets for tuberculosis treatment success among HIV-positive patients in New York City. International Journal of Tuberculosis and Lung Disease
2010; 14: 1613–1620.
Marais, BJ, et al.
Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infectious Diseases
2013; 13: 436–448.
Alisjahbana, B, et al.
The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clinical Infectous Diseases
2007; 45: 428–435.
Faurholt-Jepsen, D, et al.
Diabetes is a strong predictor of mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients from Mwanza, Tanzania. Tropical Medicine & International Health
2013; 18: 822–829.
Metcalfe, JZ, et al.
Tuberculosis and HIV co-infection, California, USA, 1993–2008. Emerging Infectious Diseases
2013; 19: 400–406.
Chien, JY, et al.
Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. International Journal of Tuberculosis and Lung Disease
2010; 14: 616–621.
Pan, L, et al.
Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus. World Jounral of Gastroenterology
2005; 11: 2518–2521.
Wong, WM, et al.
Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology
2000; 31: 201–206.
Ungo, JR, et al.
Antituberculosis drug-inducted hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. American Journal of Respiratory and Critical Care Medicine
1998; 157: 1871–1876.
Campo, M, et al.
Characterization of hepatitis C infection in tuberculosis patients in an urban city in the USA. Epidemiology and Infection
2014; 142: 1459–1466.
Sirinak, C, et al.
Viral hepatitis and HIV-associated tuberculosis: risk factors and TB treatment outcomes in Thailand. BMC Public Health
2008; 8: 245.
Padmapriyadarsini, C, et al.
Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function. Journal of Postgraduate Medicine
2006; 52: 92–96.
Zhang, L, et al.
High prevalence of HIV, HCV and tuberculosis and associated risk behaviors among new entrants of methadone maintenance treatment clinics in Guangdong Province, China. PLoS ONE
2013; 8: 1–10.
Richards, DC, et al.
High prevalence of hepatitis C virus but not HIV co-infection among patients with tuberculosis in Georgia. International Journal of Tuberculosis and Lung Disease
2006; 10: 396–401.
Reis, NRS, et al.
Hepatitis C virus infection in patients with tuberculosis in central Brazil. International Journal of Tuberculosis and Lung Disease
Kuniholm, MH, et al.
Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients. International Journal of Infectious Diseases
2008; 12: 51–56.
Wang, JY, et al.
Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. Journal of Infection
Aires, RS, et al.
Prevalence of hepatitis B virus infection among tuberculosis patients with or without HIV in Goiânia City, Brazil. Journal of Clinical Virology
2012; 54: 327–331.
Lomtadze, N, et al.
Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS ONE
2013; 8: 1–11.
France, AM, et al.
Estimating the prevalence of chronic hepatitis B virus infection – New York City, 2008. Journal of Urban Health
2012; 89: 373–383.
Centers for Disease Control and Prevention. Rec-ommendations for identification and public health management of persons with chronic hepatitis B virus infection. Morbidity and Mortality Weekly Report
2008; 57: 1–20.
Balter, S, et al.
Estimating the prevalence of hepatitis C infection in New York City using surveillance data. Epidemiology and Infection
2014; 142: 262–269.
Chak, E, et al.
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver International
2011; 31: 1090–1101.
Drobnik, A, et al.
Matching HIV, tuberculosis, viral hepatitis and sexually transmitted diseases surveillance data, 2000–2010: identification of infectious disease syndemics in New York City. Journal of Public Health Management and Practice
2014; 20: 506–512.
Ahuja, S, et al.
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Medicine
2012; 9: 1–16.
McGibbon, E, Bornschlegel, K, Balter, S.
Half a diagnosis: gap in confirming infection among hepatitis C antibody-positive patients. American Journal of Medicine
2013; 126: 718–722.
Mahajan, R, et al.
Mortality among persons in care with hepatitis C virus infection – the chronic hepatitis cohort study (CHeCS), 2006–2010. Clinical Infectious Diseases
Chastain, C, Naggie, S.
Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014. Current HIV/AIDS Reports
2013; 10: 408–419.
Lawitz, E, et al.
Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine
2013; 368: 1878–1887.
Klein, PW, et al.
HIV testing of tuberculosis patients by public and private providers in New York City. Journal of Community Health
2013; 39: 494–502.
Sylvestre, DL, et al.
Co-occurring hepatitis C, substance use and psychiatric illness: treatment issues and developing integrated models of care. Journal of Urban Health
2004; 81: 719–734.
Beijer, U, Wolf, A, Fazel, S.
Prevalence of tuberculosis, hepatitis C virus and HIV in homeless people: a systematic review and meta-analysis. Lancet Infectious Dis-eases
2012; 12: 859–870.